Ian is non-voting Chairman of the Voting Panel. 

He is a Director of Ford Sinclair Ltd., Chairman of Design Portfolio Marketing Services Ltd. and a member of the Investor Relations Society.

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding Design Portfolio in 1991, he has been active in helping many companies with their investor communication and corporate reporting requirements.

Mette has broad international experience within biotech and life sciences both as an investor, as a board member, and operationally, covering business development and licensing, management and financing. 

Mette has been appointed to numerous board positions in both private and public companies in Europe and the US. She currently has six board positions in the US and Europe and work as strategic advisor for several companies and initiatives.

Mette previously founded and managed Lundbeckfonden Ventures, completing around 40 European and US investments over a 12 year period, and was part of the management at the Lundbeck Foundation. Before that, she was co-founder and CEO of 7TM Pharma A/S. She started her biotech career as part of the management team of NeuroSearch A/S, responsible for business development and licensing.

Mette started as a patent agent and, over the years, has co-founded several biotech companies. Mette graduated as a biologist from the University of Copenhagen and has an MBA from Henley Business School.

Renée has been CEO of Calliditas Therapeutics AB since 2017 and previously spent 12 years as an investor in Life Sciences. She was a Partner and COO of Omega Funds prior to which she served as a Partner in the Venture Capital group 3i Group plc in London where she was responsible for managing its publicly quoted assets and European legacy healthcare portfolio. Prior to this, she was a European Group Head and MD in investment banking and has over twelve years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on M&A and raising private and public capital for growth companies in both Europe and the US. Prior to investment banking, Renée worked for five years in European sales and marketing for a financial services-focused software business. Renée has a BA in Finance from Stockholm School of Economics and an MBA from INSEAD. She has significant Board experience from both private and public US and European Board work.

Lisa Anson is an experienced leader in the global biotech and pharmaceutical sector. As CEO of Redx Pharma since 2018, she has led the transformation of Redx into a significant UK-based clinical-stage biotechnology company focused on fibrotic disease and cancer. Under her stewardship the Company has grown significantly, delivering five drug candidates to the clinical stage of development and establishing a growing pipeline of preclinical assets. During this time, the Company has also secured major partnership deals with large and speciality pharma and secured a series of financings with a range of blue-chip life science focused investors.

Dr. Hubert Birner a Managing Partner of TVM Capital and responsible for the company’s worldwide venture capital strategy for life sciences. He has been with TVM since October 2000. Hubert has had one of the longest active careers in European Venture Capital and has successfully managed/overseen more than 50 investments for TVM. In total, he is overseeing all portfolio investments from 4 TVM funds currently.

He currently serves as Chairman of the Board of AL-S Pharma AG (Zurich, Switzerland), leon-nanodrugs (Munich, Germany) and Spepharm Holdings BV (Amsterdam, the Netherlands), he is also a Supervisory Board Member of Centogene AG (NASDAQ).

For many years, he has been the Chairman/Vice Chairman of the Board of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany, XETRA) which were both acquired by Bayer HealthCare AG and Shire Ltd. as the largest acquisitions in the history of Germany biotechnology. It is also noteworthy that his investments in Horizon Therapeutics and Evotec triggered their transformation into multi-billion-dollar public companies today.

Hubert has also successfully designed and implemented a new “asset centric” project financing investment model for biotechnology/early pharmaceutical companies in close cooperation with Eli Lilly & Company.

Prior to his tenure at TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany for Zeneca Agrochemicals, headquartered in London, UK. In this context, Hubert did manage his first biotechnology investments. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.

Hubert also holds an MBA from Harvard Business School.

Tracy has more than 25 years of communications and leadership experience, working with diverse stakeholders and senior executives in healthcare, across a range of disciplines including corporate communications, media relations, investor relations, issues and crisis management, employee engagement, change management, public affairs and marketing communications.

Prior to joining Consilium in 2022, Tracy was Chief Communications Officer at COMPASS Pathways, a Nasdaq-listed mental health care company, where she developed and led communications through a number of financing rounds, including IPO, and several clinical data milestones.

Tracy began her career in communications consultancy, working at Rowland Sallingbury Casey and Brunswick. She has since led in-house communications teams in healthcare and life sciences organisations including Amersham International, GE Healthcare Medical Diagnostics, Essentia (part of Guy’s and St Thomas’ NHS Foundation Trust), and COMPASS Pathways. She has worked in the UK and the US, and has a BSc in Natural Sciences from Durham University.

Managed IBT since 2006 and took over as co-lead manager in March 2021.  Before moving to Schroders with IBT, Ailsa was managing the trust at SV Health Investors. She started her career at Insight Investment / Rothschild Asset Management (merged 2003) within the Global/US investment team and then worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks.

Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.

Victoria joined J.P. Morgan Asset Management in the European Research team covering the healthcare sector over fifteen years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.

John A. Dawson, CBE, is a highly experienced and globally respected figure in the healthcare sector. 

Most recently, he was Chief Executive Officer of Oxford Biomedica where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, and delivered multiple high value partnerships. The company successfully manufactured the life-saving Oxford/AstraZeneca COVID-19 vaccine in early 2021.

Under John’s leadership, Oxford Biomedica’s success resulted in it entering the FTSE 250 index in 2020. John was subsequently awarded a CBE for services to UK life science in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine.

Prior to Oxford Biomedica, John held various senior executive roles including at Cephalon, Inc. where for most of his tenure he was Managing Director for Europe. 

Prior to this, he served as the Financial Director for Serono UK. Mr. Dawson is a Chartered Accountant and holds a BSc in Mathematics from Swansea University. 

John is a non-executive director at Ergomed, which provides specialized services to the pharmaceutical industry, Chinese Speciality Pharma Ltd., which brings innovative specialty and rare disease products to China, and Norgine, a leading European specialist pharmaceutical company that has been bringing transformative products to patients for over a century.

Chris has worked as an equity research analyst focused on the healthcare sector for over 20 years, covering pharmaceuticals, medical technology and services within the industry.

Over his career, Chris has worked for both Buy and Sell side businesses, including AXA Investment Management, Dresdner Kleinwort and Evolution Securities. He joined Cenkos (now Cavendish) to cover small-cap Healthcare in 2016.

Prior to moving into the City, Chris completed a degree in Biochemistry and PhD in Nutrition.

Liam joined the team at SP Angel in 2019 where he helped set up the healthcare franchise for the firm. Prior to SP Angel he worked at Northland Capital Partners covering small and mid-cap healthcare companies. 

Liam holds BSc and MSc degrees in Biological Sciences from the University of Bristol and Imperial College London.

Stef runs an independent advisory business that enables clients including established life science companies, start-ups and investors in the life sciences ecosystem to formulate their strategies, raise finance and fulfil their potential. Previously, he was a top ranked life sciences analyst in London where he built two #1 franchises that dominated UK life sciences investment banking for over ten years and helped advise, finance, and build some of the most successful companies in the UK sector, including billion-dollar-plus successes such as Abcam, Oxford Nanopore and Syncona.

Anne has been Managing Partner of MC Services since 2011 and has over 20 years of experience in Financial and Strategic Communications. She was responsible for setting up the MC Services office in Düsseldorf and building the team and operations there. Prior to that, she held senior management positions in international pharma and biotech companies. She headed the Investor Relations and Corporate Communications department of Evotec AG for 10 years and was a member of the company’s Executive Committee. Previously, she was responsible for Investor Relations and Corporate Communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and Nasdaq, multiple M&A programs and major financial transactions. Anne is a pharmacist and marketing expert by training. Her sector expertise includes pharma and life sciences with experience in all major indication areas.

Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to joining Stifel, Max was Chief Financial Officer of Silence Therapeutics plc. He possesses more than 25 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks. He has also been involved in raising over $1bn for biotech companies. 

Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Accountant with Arthur Andersen.

Uli is a Managing Director at goetzpartners. He is responsible for the Industry Group Healthcare. He is a founding partner of Code Securities Limited, a specialist life science investment bank which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013. As Director, Corporate Finance, Ulrich Kinzel was instrumental for building the continental European M&A and Equity Capital Markets business. He was previously a Director of WestLB Panmure’s Life Science Team. He has advised leading international live science companies in more than 60 successful M&A and ECM transactions, including cross-border European, Asian and US public and private takeovers as well as IPOs and secondary offerings on all major European Stock Exchanges. He holds a master’s degree in Business Administration from Munich University.

Emily is a Director of the Life Sciences and Healthcare Team at HSBC Innovation Banking, in London. She supports innovative biopharma & diagnostic clients across the EMEA region and works with founders, C-suite and investors to provide banking and lending solutions that support client innovation and growth.

Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She is currently working at Polar Capital, which she joined in September 2021, as a consultant focused on independent research for the team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital.

Previously Tara spent over 15 years working in equity research, specialising in European pharmaceuticals, biotechnology and medtech at Lehman Brothers and Jefferies. She has also worked with a number of healthcare-focused startups through her life sciences consultancy, SSquared Consulting, most recently working with the UK government’s Vaccine Taskforce.

Craig is a Partner in IP Group’s Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome, followed by a series of business development roles in UK biotech. He was then part of the founding management team of an in vitro diagnostics company before moving into venture capital investment with Inventages, a life science focused VC fund. He subsequently worked for Fusion IP plc, a specialist investor in university spin-out companies, before joining IP Group in 2014.

Craig has a first-class honours degree in Pharmacy from Cardiff University and a PhD from the School of Pharmacy, University of Nottingham. He also holds an MBA with Distinction from the University of Warwick where he was awarded a Sainsbury Management Fellowship from the Royal Academy of Engineering.

Nick is an experienced Non-executive Director and Chairman with a background as a successful corporate financier. He has considerable experience of businesses in the Healthcare, Medical, Biotechnology, Environmental and Technology sectors. Nick is chairman of SEHTA, one of the largest health technology networking organisations in the UK. He is also a non executive director of Cambridge Cognition Holdings plc.  In 2021 he helped sell Alcuris, an emerging Telecare and Telehealth business to Access Group. Until 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company and, through Ipso Ventures, he helped found Therakind, a successful developer of paediatric medicines.

Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 20 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.

Tim is a Director at FTI Consulting and a Life Sciences and Healthcare specialist within the company’s strategic communications segment. Tim focuses on building and protecting the reputations of biotech, pharma, medtech and healthcare companies through corporate, financial and brand communications. He works with a range of private and listed clients across the industry as they navigate rapidly changing environments, communicate key milestones, prepare for crises, and engage with capital markets. 

Mark has 25+ years of experience in the life sciences sector, spent in communications, journalism and publishing. With 20+ years of agency experience, Mark provides advice and manages communication programs for private and public companies, and specialist VCs. He also has six years of experience as an Editor for biotech business publications and leading peer-reviewed journal. Mark holds a PhD in Molecular Biology from the University of London.

Michael White is the Head of Life Sciences at HSBC Innovation Banking. Mike leads a talented life sciences team that delivers HSBC Innovation Banking’s specialised banking and lending products to high-growth public and private life science companies. These companies range from private venture-backed to publicly traded, with market caps ranging from $100 million to $5 billion.

Prior to this, Mike was the National Head of Life Sciences Business Development and Co-Manager of the Silicon Valley Bank San Diego office. Mike has also spent time in leadership roles at GE Capital in San Francisco, CA and Oracle Corporation in Redwood Shores, CA. 

Mike holds a BA in English with a minor in Business from the University of Arizona, has attended corporate finance courses at UC Berkeley, and recently attended USC Marshall’s Leadership Development workshop.